Cutaneous adverse reaction to 2-chlorodeoxyadenosine with histological flame figures in patients with chronic lymphocytic leukaemia

Journal of the European Academy of Dermatology and Venereology

Volumn 18, Issue 5, 2004, Pages 538-542

  Rossini, M S ^a   de Souza, E M ^a   Cintra, M L ^a   Pagnano, K B ^a   Chiari, A C ^a   Lorand Metze, I ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

2 chlorodeoxyadenosine; Chronic lymphocyctic leukaemia; Eosinophil; Flame figures

Indexed keywords

CHLORAMBUCIL; CIPROFLOXACIN; CLADRIBINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; FLUCONAZOLE; PREDNISONE; PURINE DERIVATIVE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL OBSERVATION; CYTOPENIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG WITHDRAWAL; EOSINOPHIL; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNE DEFICIENCY; INFLAMMATORY INFILTRATE; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SKIN BIOPSY; T LYMPHOCYTE ACTIVATION; WELLS SYNDROME;

AGED; ANTINEOPLASTIC AGENTS; CLADRIBINE; DIAGNOSIS, DIFFERENTIAL; DRUG ERUPTIONS; EXANTHEMA; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MIDDLE AGED;

EID: 4544238828     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2004.00969.x     Document Type: Article

References (32)

1. Piro LD, Carrera CJ, Beutler E, Carson DA. 2-Chlorodeoxyadenosine: An effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988; 72: 1069-1073.
2. Robak T, Blonski JZ, Urbanska-Rys H, Blasinska-Morawiec M, Skotnicki AB. 2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger. Leukemia 1999; 13: 518-523.
3. Robak T, Blonski JZ, Kasznicki M et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000; 96: 2723-2729.
4. Crews KR, Gandhi V, Srivastava DK et al. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol 2002; 20: 4217-4224.
5. Bryant J, Clegg A, Milne R. Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis. J Neurol Neurosurg Psychiatry 2001; 70: 574-579.
6. Suenaga K, Kanda Y, Niiya H et al. Successful application of nonmyeloablative transplantation for paroxysmal nocturnal hemoglobinuria. Exp Hematol 2001; 29: 639-642.
7. Seymour JF, Kurzrock R, Freireich EJ, Estey TH. 2-Chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood 1994; 83: 2906-2911.
8. Kong LR, Huang CF, Hakimian D et al. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma. Cancer 1998; 82: 957-964.
9. Meunier P, Castaigne S, Bastie JA, Chosidow O, Aractingi S. Cutaneous reactions after treatment with 2-chlorodeoxyadenosine. Acta Derm Venereol 1996; 76: 385-386.
10. Rutella S, Sica S, Rumi C et al. Hypereosinophilia during 2-chlorodeoxyadenosine treatment for hairy cell leukemia. Br J Haematol 1996; 92: 426-428.
11. Grey MR, Flanagan NG, Kelsey PR. Severe skin rash in two consecutive patients treated with 2-chlorodeoxyadenosine for hairy cell leukaemia at a single institution. Clin Lab Haematol 2000; 22: 111-113.
12. Robak T, Sysa-Jedrzejowska A, Robak E, Dabkowski J, Blasinska-Morawiec M. 2-Chlorodeoxyadenosine (cladribine) induced allergic cutaneous reactions with eosinophilia in a patient with B-cell chronic lymphocytic leukemia. J Med 1997; 28: 199-209.
13. Bigby M. Incidence, prevalence and the rates of cutaneous reactions to drugs. J Eur Acad Dermatol Venereol 2000; 14: 435.
14. Cetkovska P, Pizinger K, Cetkovsky P. High-dose cytosine arabinoside-induced cutaneous reactions. J Eur Acad Dermatol Venereol 2002; 16: 481-485.
15. Wells GC. Recurrent granulomatous dermatitis with eosinophilia. Trans St Johns Hosp Dermatol Soc 1971; 57: 46-56.
16. Consigny S, Courville P, Young P et al. Formes anatomocliniques du syndrome de Wells. Ann Dermatol Venereol 2001; 128: 213-216.
17. Aberer W, Konrad K, Wolff K. Wells' syndrome is a distinctive disease entity and not a histologic diagnosis. J Am Acad Dermatol 1988; 18: 105-114.
18. Caballero MJ, Santos SP, Martinez GB, Echeverria ML, Ochaíta PL. Wells'syndrome and human immunodeficiency virus infection. Br J Dermatol 2000; 143: 672-674.
19. Seçkin D, Demirhan B. Drugs and Wells'syndrome: a possible causal relationship? Int J Dermatol 2001; 40: 133-140.
20. Schorr WF, Tauscheck AL, Dickson KB, Melski JW. Eosinophilic cellulitis (Wells' syndrome). Histologic and clinical features in arthropod bite reacions. J Am Acad Dermatol 1984; 11: 1043-1049.
21. Tsuda S, Tanaka K, Miyasato M, Nakama T, Sasai Y. Eosinophilic cellulitis (Well's syndrome) associated with ascariasis. Acta Derm Venereol 1994; 74: 292-294.
22. Hurni MA, Gerbig AW, Braathen LR, Hunziker T. Toxocariasis and Wells' syndrome: a causal relationship? Dermatology 1997; 195: 325-328.
23. Wells GC, Smith NP. Eosinophilic cellulitis. Br J Dermatol 1979; 100: 101-109.
24. Reichel M, Isseroff RR, Vogt PJ, Gandour-Edwards R. Wells' syndrome in children: varicella infection as a precipitating event. Br J Dermatol 1991; 124: 187-190.
25. Wenzel J, Boehm I, Gerdsen R, Bieber T, Uerlich M. Flame figures in urticarial lesions accompanying systemic lupus erythematosus. Am J Dermatopathol 2001; 23: 533-535.
26. Garty BZ, Feinmesser M, David M, Gayer S, Danon YL. Congenital Wells' syndrome. Pediatr Dermatol 1997; 14: 312-315.
27. Bogenrieder T, Griese DP, Schiffner R et al. Wells'syndrome associated with idiopathic hypereosinophilic syndrome. J Dermatol 1997; 137: 978-982.
28. Lee SC, Shin SS, Lee JB, Wen YH. Wells' syndrome associated with Churg-Strauss syndrome. J Am Acad Dermatol 2000; 43: 556-557.
29. Peters MS, Schroeter AL, Gleich GJ. Immunofluorescence identification of eosinophil granule major basic protein in the flame figures of Wells' syndrome. Br J Dermatol 1983; 109: 141-148.
30. Selvaag E, Roald B. Eosinophil activation in Wells'syndrome demonstrated immunohistochemically with antibodies against eosinophilic cation protein. (Letter). Acta Derm Venereol 2000; 80: 63-64.
31. España A, Sanz ML, Sola J, Gil P. Wells'syndrome (eosinophilic cellulitis): correlation between clinical activity, eosinophil levels, cosinophil cationic protein and interleukin-5. Br J Dermatol 1999; 140: 127-130.
32. Trüeb RM, Lübbe J, Torricelli R, Panizzon RG, Wathrich B, Burg G. Eosinophilic myositis with cosinophilic cellulitis-like skin lesions. Association with increased serum levels of eosinophil cationic protein and interleukin-5. Arch Dermatol 1997; 133: 203-206.